Brief: Aptahem: Ongoing Pre-Clinical Toxicology Development Program Is Delayed

Aptahem AB

29/08/2018 07:24

Aug 29 (Reuters) - Aptahem AB  APTA.TE :
    * APTA-1 HAS IN THE ONGOING TOXICOLOGY PROGRAM INDICATED A
GOOD
SAFETY PROFILE THAT RESULTED IN A GREATER SUBSTANCE NEED, WHICH
DELAYS THE PROGRAM
    * OVERALL SITUATION MEANS THAT PLANNED START OF CLINICAL
TRIALS IS
ESTIMATED TO Q3 2019
    * SAYS RESULTS ALSO INDICATE THAT DOSAGES CAN BE INCREASED
IN
ONGOING EFFICACY STUDY IN NHP (NON HUMAN PRIMATE)
    * SAYS TIME REQUIRED FOR MANUFACTURING OF NEW SUBSTANCE
CAUSES A
DELAY OF START OF REGULATORY GLP TOXICOLOGY

Source text for Eikon:  ID:nWkr9w5Rln 
Further company coverage:  APTA.TE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))